Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
bluebird bio股价上涨,因该公司宣布加入CMMI电芯和基因疗法准入模型,并将提供基于结果的协议,以扩大LYFGENIA镰状细胞病基因疗法在医疗补助方面的覆盖范围。
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
bluebird bio的股票在公司宣布加入CMMI电芯和基因治疗获取模式并将提供基于结果的协议以扩大Medicaid对LYFGENIA基因治疗镰状细胞病的获取后上涨。